UBiome

Last updated
uBiome, Inc.
Company type Private
Industry Biotechnology
Founded2012
FounderZachary Apte, Jessica Richman
Defunct2019
FateBankruptcy in 2019 after federal fraud charges in 2021. Founders are FBI fugitives.
Headquarters
San Francisco, California
,
United States
Products
  • SmartGut
  • SmartJane
  • Explorer
Website ubiome.com (archived link)

uBiome, Inc. was a biotechnology company based in San Francisco that developed technology to sequence the human microbiome. Founded in 2012, the company filed for bankruptcy in 2019 following an FBI raid in an investigation over possible insurance fraud [1] [2] involving the US health insurance program Medicare. [3]

Contents

In 2021, the Securities and Exchange Commission charged two of the cofounders (Richman and Apte) with defrauding investors. [4] [5] The couple were also charged with federal crimes including conspiracy to commit fraud and money laundering. [6] Since 2021, the FBI has considered the founders to be fugitives. [7] [8]

History

Founding

The company was founded by Jessica Richman, Zachary Apte, and Will Ludington who were scientists in the California Institute for Quantitative Biosciences. [9] In November 2012, uBiome generated $350,000 through a crowdfunding campaign. [10] The founders received mentoring and funding from Y Combinator and further funding from Andreessen Horowitz and 8VC. [11] [12] [13]

Jessica Richman was also found to have lied about her age to get on tech lists such as Forbes 30 under 30. She was in her forties at the time.

Insurance fraud investigation and liquidation

In April 2019, FBI agents raided the uBiome office in an investigation over possible insurance fraud [1] [2] involving the US health insurance program Medicare. [3] According to company insiders, the company often repeatedly billed patients without their consent and pressured doctors to approve tests. [14]

Cofounders Apte and Richman were put on administrative leave pending an investigation by the company's board. [15]

The company filed for Chapter 11 bankruptcy (reorganization of debt) in September 2019, amidst the investigation, [16] and less than a month later it filed for a Chapter 7 bankruptcy (liquidation) and shut down. [3]

In 2021, the Securities and Exchange Commission charged two of the cofounders (Richman and Apte) with defrauding investors. [4] [5] The couple were also charged with federal crimes including conspiracy to commit fraud and money laundering. [6] Richman and Apte married in 2019 and relocated to Germany in June 2020. Since 2021, the FBI has considered them to be fugitives. [7]

Products and services

Customers purchase kits to sample one or more parts of their body, including the gut, genitals, mouth, nose, or skin. After swabbing, a participant takes a survey which is used to make correlations with microbiome data. The participant sends the kit to the company in the mail and receives data in a few weeks; they can compare their data with that of uBiome's data set. [17] [18] In 2015 uBiome received Clinical Laboratory Improvement Amendments (CLIA) certification from the State of California. [19] In 2016, uBiome received accreditation from the College of American Pathologists. [20]

Technology

As of 2015, the company first amplified a portion of the bacterial gene that encodes 16S ribosomal RNA using PCR, then sequenced the amplified 16S ribosomal RNA gene, in order to categorize the bacteria at the genus level. [21] The company had proprietary machine learning algorithms that analyzed the sequence data and compared it with the company's proprietary database of microbiomes, built from the samples that partners[ clarification needed ] and single[ clarification needed ] customers sent to them, and web-based software that allowed individuals to view their microbiome and make certain comparisons. [22] [23] A 2014 report in Xconomy said the company outsourced the sequencing. [23] The sequencing was done on the Illumina NextSeq500 sequencer. [24] [25]

In October 2015 the company introduced an app on iOS using ResearchKit that allowed customers to view their results on mobile devices. [26]

uBiome has been compared with Theranos and 23andMe, each of which was also a biotechnology company influenced by Silicon Valley. [27] [28]

Citizen science

Amy Dockser Marcus noted in a 2014 essay in The Wall Street Journal that when uBiome raised its initial round of crowdfunding in early 2013, many questions were raised by bioethicists about the company's citizen science business model — namely whether it had actually obtained informed consent from its customers, and whether direct to consumer genetic testing initiatives could be ethically conducted at all, and its lack of institutional review board (IRB) approval. [29] [30] [31] The Wall Street Journal essay also noted that questions were raised about the quality of data obtained in citizen science initiatives, with regard to self-selection and other issues. [29] [32]

The company obtained an institutional review board approval in July 2013. [29] [33] [34]

In 2014, people experienced in biotechnology entrepreneurship also raised questions about the ethics of crowdfunding a biotech company, as the risks of such ventures are high even for people with scientific and business sophistication. [29] [35]

As of 2015, uBiome offered a $1 million grant program to researchers and citizen scientists for microbiome sampling and related analysis. [36] One winner of the first round of such grants was the Centers for Disease Control and Prevention. [27]

Awards and recognition

In March 2018, uBiome made Fast Company's list for The World's Most Innovative Companies in Data Science, acknowledging uBiome's work collecting data to develop tests for HPV and STIs. [37]

See also

Related Research Articles

<span class="mw-page-title-main">23andMe</span> American personal genomics company

23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.

<span class="mw-page-title-main">Anne Wojcicki</span> American entrepreneur (born 1973)

Anne E. Wojcicki is an American entrepreneur who co-founded and is CEO of the personal genomics company 23andMe. She founded the company in 2006 with Linda Avey and Paul Cusenza. She is a co-founder and board member of the Breakthrough Prize.

Deborah Needleman is an American editor and writer. She was editor-in-chief of T: The New York Times Style Magazine and WSJ.. She was also the creator of the paper's weekend lifestyle section and the founding editor-in-chief of Domino magazine.

<span class="mw-page-title-main">David Berry (inventor)</span> American businessperson

David Berry is an American entrepreneur and business executive. He has co-founded Valo Health, Seres Therapeutics, Indigo Agriculture, Axcella Health, and contributed to the early development of Moderna.

Andreessen Horowitz is a private American venture capital firm, founded in 2009 by Marc Andreessen and Ben Horowitz. The company is headquartered in Menlo Park, California. As of April 2023, Andreessen Horowitz ranks first on the list of venture capital firms by assets under management, with $42 billion as of May 2024.

Angela Benton is an American businesswoman. Benton founded NewME (acquired), the first startup accelerator for minorities globally in 2011. She is a pioneer of diversity and one of the most important African-Americans in the technology industry. She has helped minority-led tech companies raise over $47 million in venture capital funding.

Laboratory developed test (LDT) is a term used to refer to a certain class of in vitro diagnostics (IVDs) that, in the U.S., were traditionally regulated under the Clinical Laboratory Improvement Amendments program.

<span class="mw-page-title-main">FundRazr</span> Canadian crowdfunding site

FundRazr is a free crowdfunding and online fundraising platform released in 2009. FundRazr operates internationally in 35+ countries with the largest markets being United States, Canada, United Kingdom and Australia. It allows users to run a wide-range of crowdfunding campaigns by creating fundraising pages and sharing it via social media, messaging apps, email and more to raise money for over 100 types of causes such as nonprofit, medical care, education, community help, poverty alleviation, arts, memorials, and animal rescue causes. FundRazr also works with more than 4000 nonprofits, charities and social enterprises with an advanced fundraising toolset for free. The digital fundraising platform provides 8 different campaign types. They include microproject fundraising, peer-to-peer campaigns, wishlist campaigns, recurring donations, branded sponsorship campaigns, DIY projects, sweepstake campaigns, and storefront campaigns.

<span class="mw-page-title-main">Geoffrey von Maltzahn</span> American inventor

Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics.

Jumio is an online mobile payment and identity verification company that provides card and ID scanning and validation products for mobile and web transactions, which they sell as "Netverify Trusted Identity as a Service".

Theranos Inc. was an American privately held corporation that was touted as a breakthrough health technology company. Founded in 2003 by then 19-year-old Elizabeth Holmes, Theranos raised more than US$700 million from venture capitalists and private investors, resulting in a $10 billion valuation at its peak in 2013 and 2014. The company claimed that it had devised blood tests that required very small amounts of blood and that could be performed rapidly and accurately, all using compact automated devices that the company had developed. These claims were proven to be false.

<span class="mw-page-title-main">Elizabeth Holmes</span> American businesswoman (born 1984)

Elizabeth Anne Holmes is an American biotechnology entrepreneur who was convicted of fraud in connection to her blood-testing company, Theranos. The company's valuation soared after it claimed to have revolutionized blood testing by developing methods that needed only very small volumes of blood, such as from a fingerprick. In 2015, Forbes had named Holmes the youngest and wealthiest self-made female billionaire in the United States on the basis of a $9-billion valuation of her company. In the following year, as revelations of fraud about Theranos's claims began to surface, Forbes revised its estimate of Holmes's net worth to zero, and Fortune named her in its feature article on "The World's 19 Most Disappointing Leaders".

<span class="mw-page-title-main">John Carreyrou</span> American journalist and author

John Carreyrou is a French-American investigative reporter at The New York Times. Carreyrou worked for The Wall Street Journal for 20 years between 1999 and 2019 and has been based in Brussels, Paris, and New York City. He won the Pulitzer Prize twice and is well known for having exposed the fraudulent practices of the multibillion-dollar blood-testing company Theranos in a series of articles published in The Wall Street Journal.

Ramesh "Sunny" Balwani is a businessman, former president and chief operating officer of Theranos, which was a privately held health technology company founded by his then-girlfriend Elizabeth Holmes. He and Holmes fraudulently represented that they had devised a revolutionary blood test that required only small amounts of blood, such as from a fingerstick. Both Balwani and Holmes were convicted of fraud. The consequences of the fraud led to the collapse of Theranos and the loss of billions of dollars to investors.

<i>Bad Blood: Secrets and Lies in a Silicon Valley Startup</i> 2018 book by John Carreyrou

Bad Blood: Secrets and Lies in a Silicon Valley Startup is a nonfiction book by journalist John Carreyrou, released May 21, 2018. It covers the rise and fall of Theranos, the multibillion-dollar biotech startup headed by Elizabeth Holmes. The book received critical acclaim, winning the 2018 Financial Times and McKinsey Business Book of the Year Award.

<span class="mw-page-title-main">Ian Gibbons (biochemist)</span> British biochemist (1946-2013)

Ian Gibbons was a British biochemist and molecular biology researcher who served as the chief scientist of the US company Theranos, which was founded by Elizabeth Holmes. For more than 30 years, Gibbons performed research in medical therapeutics and diagnostic testing prior to joining Theranos in 2005. He attempted to raise issues with Theranos' management about the inaccuracy of their testing devices.

Embark is a canine genomics and biotechnology company based in Boston, Massachusetts. The company offers dog DNA testing services to consumers, breeders, and veterinarians.

<i>The Inventor: Out for Blood in Silicon Valley</i> 2019 American documentary film

The Inventor: Out for Blood in Silicon Valley is a 2019 American documentary film, directed and produced by Alex Gibney. The film revolves around Elizabeth Holmes and her former company Theranos. It is considered a companion piece to the book, Bad Blood: Secrets and Lies in a Silicon Valley Startup.

Channing Rex Robertson is a professor emeritus of chemical engineering at Stanford University. He held multiple significant roles at startup Theranos, founded by his student Elizabeth Holmes. Robertson took on major responsibilities at the company prior to its collapse, including becoming its first board member, engaging with venture capitalists, and recruiting biochemist Ian Gibbons. He retired from Stanford in 2012, becoming professor emeritus. Theranos named him the co-leader of their technology advisory board in 2017. He was called as a witness in United States v. Elizabeth A. Holmes, et al., which convicted Holmes and partner Sunny Balwani of criminal fraud. During his time working for Holmes, Robertson was paid US$500,000 per year by Theranos. Since his active role in the Theranos scandal, he went back to teach one course at Stanford.

<i>United States v. Elizabeth A. Holmes, et al.</i> Criminal fraud case

United States v. Elizabeth A. Holmes, et al., was a United States federal criminal fraud case against the founder of now-defunct corporation Theranos, Elizabeth Holmes, and its former president and COO, Ramesh Balwani. The case alleged that Holmes and Balwani perpetrated multi-million dollar wire-fraud schemes against investors and patients. Holmes and Balwani each had their own jury trial.

References

  1. 1 2 Shin, Sally (April 26, 2019). "uBiome office in San Francisco getting raided by FBI San Francisco division special agents Video from @ltbatch on the ground pic.twitter.com/GO4Sb2LFMO". @sallyshin. Retrieved April 26, 2019.
  2. 1 2 Mathews, Anna Wilde; Marcus, Amy Dockser (April 26, 2019). "FBI Searches Microbiome Testing Startup in Billing Probe". Wall Street Journal. ISSN   0099-9660 . Retrieved April 26, 2019.
  3. 1 2 3 "uBiome to Close Doors One Month After Bankruptcy Filing". BioSpace. October 2, 2019. Retrieved March 9, 2021.
  4. 1 2 SFGATE, Katie Dowd (March 21, 2021). "SF couple who ran trendy poop-testing startup charged with fraud". SFGATE. Retrieved March 23, 2021.
  5. 1 2 "SEC.gov | SEC Charges Co-Founders of San Francisco Biotech Company With $60 Million Fraud". www.sec.gov. Retrieved March 23, 2021.
  6. 1 2 Morse, Jack (March 22, 2021). "Turns out that poop-testing startup was full of it". Mashable. Retrieved March 23, 2021.
  7. 1 2 Dockser Marcus, Amy (November 24, 2021). "The Biotech Startup That Became an FBI Target". Wall Street Journal (podcast). Retrieved April 3, 2022.
  8. ↑ "Founders of poop-testing uBiome, reportedly on the run, charged by SEC with defrauding investors". Endpoints News. Retrieved February 4, 2023.
  9. ↑ Lee, Teresa (April 22, 2013). "Swabbing for Science". The Berkeley Science Review. Archived from the original on October 29, 2016. Retrieved October 29, 2016.
  10. ↑ Vachelard, J; Gambarra-Soares, T; Augustini, G; Riul, P; Maracaja-Coutinho, V (February 17, 2016). "A Guide to Scientific Crowdfunding". PLOS Biology. 14 (2): e1002373. doi: 10.1371/journal.pbio.1002373 . PMC   4757556 . PMID   26886064.
  11. ↑ Chokkattu, Julian. "uBiome Raises $4.5M From Angel Investors, Andreessen Horowitz To Crowdsource Microbiome Research". TechCrunch.
  12. ↑ Dillet, Romain. "Andreessen Horowitz Raises Massive New $1.5 Billion Fund". TechCrunch.
  13. ↑ Buhr, Sarah. "Gut health startup uBiome has raised $15.5 million and is launching a DNA test for your poop". TechCrunch.
  14. ↑ Farr, Christina (May 2, 2019). "Insiders describe aggressive growth tactics at uBiome, the health start-up raided by the FBI last week". CNBC. Retrieved March 9, 2021.
  15. ↑ Farr, Christina (May 6, 2019). "Health tech start-up uBiome suspends clinical operations following FBI raid". CNBC . Retrieved June 18, 2019.
  16. ↑ "Everything we know about uBiome, the startup that convinced Silicon Valley that testing poop was worth $600 million, and then filed for bankruptcy amid an FBI investigation". Business Insider . Retrieved May 10, 2020.
  17. ↑ Gertner, Jon (January 7, 2015). "What's Lurking In Your Microbiome? Possibly, A Cure For Disease". Fast Company.
  18. ↑ Almalki, M; Gray, K; Sanchez, FM (February 24, 2015). "The use of self-quantification systems for personal health information: big data management activities and prospects". Health Information Science and Systems. 3 (Suppl 1 HISA Big Data in Biomedicine and Healthcare 2013 Con): S1. doi: 10.1186/2047-2501-3-S1-S1 . PMC   4437547 . PMID   26019809.
  19. ↑ "uBiome Launches CLIA Lab". genomeweb. April 28, 2015.
  20. ↑ Taylor, Julie (October 4, 2016). "uBiome's Laboratory Receives Accreditation by College of American Pathologists (CAP)". PRWeb.
  21. ↑ Scoles, Sarah (October 7, 2015). "I Sent a Sample of My Poop to uBiome -". The Crux @ Discover Magazine. Archived from the original on October 29, 2016. Retrieved October 29, 2016.
  22. ↑ Khamsi, Roxanne (July 17, 2014). "Can Gut DNA Sequencing Actually Tell You Anything About Your Health?". Newsweek. Retrieved March 21, 2015.
  23. 1 2 Tansey, Bernadette (August 18, 2014). "Glowing Plants To Nanodiamonds: Y Combinator's Biotechs Debut". Xconomy.
  24. ↑ "ubiome 0.5.8 : Python Package Index". testpypi.python.org. June 17, 2016. Retrieved October 29, 2016.
  25. ↑ Mac, Tracy (June 2, 2015). "Interview with Jessica Richman of uBiome". The Power of Poop.
  26. ↑ Taylor, Nick Paul (October 11, 2015). "UBiome taps Apple ecosystem to broaden microbiome data-gathering drive". FierceBiotech.
  27. 1 2 Zhang, Sarah. “Microbiome Startup uBiome Will Sequence Poop for the CDC.” Wired. Nov. 30, 2015 Quote: "Recent controversy over the blood testing company Theranos has highlighted the sometimes loose regulations, and the Food and Drug Administration has it wants to regulate lab tests more strictly"
  28. ↑ Leonard, Andrew (December 22, 2015). "Silicon Valley Will See You Now". Modern Luxury: Silicon Valley. But a healthy dose of skepticism is also in order, not least because of the difficulties faced by the two most-celebrated digital-health startups, 23andMe and Theranos....In 2013, the FDA banned 23andMe from marketing its Personal Genome Service. The FDA, which had yet to fully sign off on the technology, was concerned "about the public health consequences of inaccurate results from the PGS devices." The lesson for the rest of the digital-health industry was clear: Unless they're expressly permitted by the FDA, companies should not encourage consumers to make medical decisions based on the health data the companies provide. ...Theranos came out of the gate with an unprecedented bang.....Then, in mid-October, an earthquake hit that rocked not just Theranos but the entire digital-health community.
  29. 1 2 3 4 Marcus, Amy Dockser (October 24, 2014). "The Ethics of Experimenting on Yourself". Wall Street Journal.
  30. ↑ DNLee (February 22, 2013). "On Ethics and Self-Policing in (Citizen) Science". Scientific American Blog Network.
  31. ↑ Chorost, Michael (September 23, 2013). "Crowdsourced Research Delves, Uncertainly, Into the Human Microbiome". The Chronicle of Higher Education.
  32. ↑ Hall, Harriet (June 25, 2013). "Meet Your Microbes: uBiome Offers New Service". Science-Based Medicine.
  33. ↑ Stone, Judy. "uBiome: Ethical Lapse or Not?". Scientific American. Retrieved February 9, 2015.
  34. ↑ Jessica, Richman; Apte, Zachary (July 22, 2013). "Crowdfunding and IRBs: The Case of uBiome". Scientific American Blog.
  35. ↑ Lee, Stephanie M. (February 15, 2014). "Biotech startup turns to crowdfunding". San Francisco Chronicle.
  36. ↑ "FACT SHEET: Announcing the National Microbiome Initiative" (PDF). obamawhitehouse.archives.gov. The White House. May 13, 2016.
  37. ↑ "The 2018 Top 10 Most Innovative Companies by Sector: Data Science | Fast Company". Fast Company. Retrieved March 26, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.